HIV and Its Life Cycle
In 1981, physicians in Los Angeles and New York noticed something impossible. Young, previously healthy gay men were dying of Pneumocystis pneumonia and Kaposi sarcoma. These diseases are normally confined to the severely immunosuppressed. No known toxin, autoimmune disease, or genetic syndrome explained the cause. Their immune systems had simply vanished. Within three years, French and American virologists had isolated the culprit. It was a retrovirus that selectively destroys CD4⁺ T lymphocytes. These are the very cells that orchestrate adaptive immunity. That virus, human immunodeficiency virus (HIV), remains one of the most intensively studied organisms in biology. This is not because it is structurally exotic. It is a small, unremarkable-looking lentivirus. Rather, its life cycle exploits nearly every layer of host-cell biology with surgical precision. HIV hijacks a chemokine receptor for entry. It reverse-transcribes its RNA genome into DNA. It permanently welds that DNA into the host chromosome. It can then either burn through the cell in a lytic burst of virions. Or it can lie dormant for years as invisible proviral DNA. This dual capacity — active replication versus true latency — explains HIV's incurability with current tools. Yet the virus remains exquisitely suppressible. Understanding HIV matters far beyond one disease. It is the paradigm for how a virus can convert the immune system's own signaling molecules into an entry apparatus. It also shows how Retroviruses and Reverse Transcription genomic integration creates a permanent cellular reservoir. And it shows how progressive loss of a single lymphocyte subset can unravel an entire immune network. That network is built on CD4⁺ helper function. The story of HIV is also a case study in modern experimental virology. Receptor identification came through resistant-cell genetics. Latency was proven through viral outgrowth assays. Depletion mechanisms were dissected through direct/bystander cell death experiments. This article walks through the molecular anatomy of entry. It covers the seven-step replication cycle and the biochemistry of proviral latency. It also covers the multiple, overlapping mechanisms by which HIV empties the CD4⁺ T-cell compartment. Each claim is grounded in the experiments that established it.
- HIV enters CD4⁺ cells via sequential binding: gp120 to CD4, then to a coreceptor (CCR5 or CXCR4), triggering gp41-mediated membrane fusion.
- Reverse transcriptase copies the RNA genome into double-stranded DNA; integrase inserts this provirus permanently into host chromatin.
- Transcription depends on host NF-κB/NFAT and the viral Tat protein, which dramatically boosts RNA Pol II elongation via the TAR RNA element.
- Latency arises when provirus integrates into resting memory CD4⁺ T cells with silenced transcription — an invisible, replication-competent reservoir that antiretroviral drugs cannot touch.
- CD4⁺ T-cell depletion results from direct viral killing, massive bystander pyroptosis of abortively infected cells, immune exhaustion, and chronic hyperactivation — not from single-cell lysis alone.
- Discovery of CCR5 as a coreceptor and of the CCR5-Δ32 mutation explained natural resistance and launched an entirely new drug class, the entry inhibitors.
HIV converts a chemokine receptor into a fusion trigger and its own reverse-transcribed DNA into a permanent, silent chromosomal parasite — making eradication, not just suppression, the central unsolved problem in AIDS biology.
The core idea
HIV is a member of the Lentivirus genus within Retroviridae, an enveloped virus carrying two copies of positive-sense single-stranded RNA genome (~9.7 kb each), tightly bound to nucleocapsid protein inside a conical capsid built from p24 protein. Studding its lipid envelope are trimeric spikes of the glycoprotein gp160, cleaved by host furin into a surface subunit gp120 and a transmembrane subunit gp41. This spike is the entire entry machine: gp120 reads host-cell identity, and gp41 executes membrane fusion. The defining molecular event of HIV biology is receptor-coreceptor sequential engagement. Unlike most enveloped viruses that bind a single receptor, HIV's gp120 first binds CD4, a glycoprotein expressed on helper T cells, monocyte/macrophages, and dendritic cells. This binding is not sufficient for entry; it instead triggers a conformational change in gp120 that exposes a second binding surface for a chemokine coreceptor — normally CCR5 (a receptor for the chemokines MIP-1α/β and RANTES) or CXCR4 (a receptor for SDF-1/CXCL12). Only after this second binding event does gp41 spring open its fusion peptide and drive membrane merger. This two-receptor logic is why HIV tropism can be classified as R5 (macrophage/early-transmitted strains), X4 (T-cell-tropic, late-stage strains), or dual-tropic. The second defining feature is the retroviral life cycle's capacity for latency: after reverse transcription and integration, the provirus can either fire transcription (productive infection, new virions, cell death) or sit transcriptionally silent in resting memory CD4⁺ T cells for the lifetime of that cell — years to decades. This silent, integrated, replication-competent DNA is the latent reservoir, and it is the central reason antiretroviral therapy controls but does not cure HIV infection.
Mechanism
Step 1 — Attachment and coreceptor engagement. A gp120 trimer on the viral envelope binds CD4 on the target cell surface with nanomolar affinity. This binding rotates the gp120 V1/V2 and V3 loops to form a bridging sheet that exposes the coreceptor-binding site. gp120 then engages CCR5 (via its V3 loop and the CCR5 N-terminus/ECL2) or CXCR4.
Step 2 — Membrane fusion. Coreceptor engagement releases gp41 from its metastable clamp. The gp41 fusion peptide inserts into the target membrane; gp41 then folds into a six-helix bundle (trimer-of-hairpins), pulling viral and cellular membranes together and driving lipid bilayer fusion. This is the step blocked by the drug enfuvirtide, a synthetic peptide that jams gp41 folding.
Step 3 — Uncoating and reverse transcription. The capsid core enters the cytoplasm and partially disassembles (uncoating) while reverse transcriptase (RT) — using a host tRNA^Lys3 primer annealed to the genomic RNA — synthesizes minus-strand DNA, degrades the RNA template via RT's RNase H domain, and synthesizes plus-strand DNA. The product is a blunt-ended, double-stranded DNA copy flanked by long terminal repeats (LTRs), assembled within a pre-integration complex (PIC). Reverse transcription is highly error-prone (roughly 1 mutation per genome per round), generating the enormous genetic diversity underlying drug resistance and immune escape.
Step 4 — Nuclear import and integration. Unlike simple retroviruses, lentiviruses can cross an intact nuclear pore, allowing HIV to infect non-dividing cells such as macrophages. Inside the nucleus, viral integrase catalyzes strand transfer, covalently inserting the proviral DNA into host chromatin, preferentially within actively transcribed genes. Integration is irreversible — the defining, incurable step.
Step 5 — Transcription. The integrated provirus is transcribed by host RNA polymerase II from the 5′ LTR promoter. Basal transcription is weak; host transcription factors NF-κB and NFAT (activated by T-cell receptor signaling) bind LTR enhancer elements to boost initiation. The viral protein Tat then binds a stem-loop RNA structure at the nascent transcript's 5′ end called TAR and recruits P-TEFb (CDK9/cyclin T1), hyperphosphorylating RNA Pol II's C-terminal domain to convert stalled, abortive transcripts into full-length processive ones — a feedback loop that massively amplifies output once triggered.
Step 6 — Splicing, nuclear export, and translation. Early transcripts are multiply spliced to produce Tat, Rev, and Nef. Rev accumulates, binds the RRE (Rev-response element) on unspliced/singly-spliced transcripts, and hijacks the CRM1 nuclear export pathway to ferry these intron-containing RNAs to the cytoplasm — RNAs that would otherwise be retained and degraded. These are translated into Gag, Gag-Pol, and Env polyproteins.
Step 7 — Assembly, budding, and maturation. Gag polyprotein drives assembly at the plasma membrane, packaging two copies of genomic RNA (via a Gag nucleocapsid-domain interaction with the RNA packaging signal, Ψ) along with Gag-Pol. The immature particle buds off, cloaked in host membrane studded with Env trimers, using the host ESCRT machinery for membrane scission. Only after budding does the viral protease cleave Gag and Gag-Pol into mature structural proteins (matrix, capsid, nucleocapsid) and enzymes (RT, integrase, protease itself), condensing the core into the mature, infectious conical capsid. This maturation step is the target of protease inhibitors.
Latency, mechanistically. Post-integration latency is established predominantly when HIV infects a CD4⁺ T cell that is transitioning to, or already is, a resting memory state — a cell with low ambient NF-κB/NFAT activity, restrictive chromatin (histone deacetylation, H3K9 methylation, DNA methylation of the LTR), and no free Tat/P-TEFb to drive elongation. Because the provirus is transcriptionally quiescent, it produces no viral protein for immune surveillance to detect, and antiretroviral drugs — which all target active replication steps (RT, integrase, protease, entry) — have nothing to act on. When that memory T cell is later reactivated by its cognate antigen (or by bystander cytokine signals), NF-κB/NFAT translocate to the nucleus, LTR transcription restarts, and the Tat–TAR positive feedback loop can rapidly convert a trickle of transcript into a burst of virions — a process called latency reversal, the basis of "shock and kill" cure strategies.
Depletion of CD4⁺ T cells occurs through several convergent, experimentally documented mechanisms, not a single one: 1. Direct cytopathic killing of productively infected cells — viral protein accumulation, membrane permeabilization during budding, and Vpr-induced cell-cycle arrest all contribute. 2. Pyroptotic death of abortively infected "bystander" cells. Most CD4⁺ T cells encountering HIV in lymphoid tissue are resting cells that permit only incomplete reverse transcription. Accumulating cytosolic DNA intermediates are sensed by the DNA sensor IFI16, activating caspase-1 and the inflammasome, triggering pyroptosis — a highly inflammatory form of cell death that releases IL-1β and recruits more activated CD4⁺ T cells to become infected. This mechanism, established by Warner Greene's group (Doitsh et al., Cell 2010; Nature 2014), accounts for the vast majority (>95% in lymphoid tissue models) of CD4⁺ T-cell death in HIV infection and explains why cell death is so disproportionate to the small fraction of cells productively infected. 3. Immune-mediated killing of infected cells by CD8⁺ cytotoxic T lymphocytes, contributing to death of the productively infected minority while imposing selection for immune-escape variants. 4. Chronic immune activation and exhaustion. Persistent antigenic stimulation, microbial translocation across a damaged gut epithelium, and inflammatory cytokines drive T cells (both infected and uninfected) toward apoptosis, senescence, and functional exhaustion (upregulation of PD-1, loss of IL-2 production), degrading immune competence even beyond raw cell counts. 5. Destruction of lymphoid architecture and thymic output, impairing the regenerative capacity that would otherwise replace lost CD4⁺ T cells. The net clinical trajectory: acute infection produces a burst of viremia and an often-silent depletion of gut-associated lymphoid tissue CD4⁺ T cells (much of it destroyed within weeks), followed by a chronic phase of gradual peripheral CD4⁺ decline (roughly 50–100 cells/μL per year untreated) and progressive immune collapse culminating in AIDS, clinically defined as CD4⁺ count below 200 cells/μL or the presence of an AIDS-defining opportunistic illness.
The evidence
Identification of HIV as the causal agent (Barré-Sinoussi, Montagnier, Gallo, 1983–1984). Françoise Barré-Sinoussi and Luc Montagnier's team at the Institut Pasteur cultured lymph node cells from a patient with lymphadenopathy, detected reverse transcriptase activity in the culture supernatant (a retroviral signature), and identified a novel retrovirus they named LAV. Robert Gallo's NIH lab independently isolated a virus (HTLV-III) from AIDS patients and developed the blood assay that confirmed the same virus in large patient cohorts, establishing the causal link to AIDS. Barré-Sinoussi and Montagnier received the 2008 Nobel Prize in Physiology or Medicine for this discovery.
Discovery of CD4 as the primary receptor (Dalgleish, Klatzman, Maddon, 1984). Multiple groups showed that antibodies against the CD4 molecule blocked HIV infection of T cells, and that transfecting the CD4 gene into normally resistant non-human cells rendered them susceptible to HIV binding (though not always full infection) — direct, causal, gain-of-function evidence that CD4 is necessary for viral attachment.
Discovery of chemokine coreceptors (1996, multiple groups). CD4 alone was known to be insufficient — CD4⁺ mouse cells remained resistant to HIV entry. The breakthrough came from a converging set of experiments: Edward Berger's lab at NIH used expression cloning to screen human cDNA libraries for a factor that rendered CD4⁺, HIV-resistant cells fusion-permissive, identifying CXCR4 ("fusin") as the coreceptor for T-cell-tropic (X4) strains. Months later, several groups — including those of Robert Doms, Paul Clapham, and Dan Littman — showed that macrophage-tropic (R5) strains instead used CCR5. Crucially, this converged with an independent clinical puzzle: some individuals with high-risk exposure remained uninfected. Sequencing revealed these individuals were homozygous for a 32-base-pair deletion in CCR5 (CCR5-Δ32), which produces a truncated, non-functional receptor never trafficked to the cell surface. Homozygotes (about 1% of people of Northern European descent) are highly resistant to R5-strain infection; heterozygotes show slower disease progression. This human genetic "experiment of nature" independently confirmed CCR5's essential, causal role in transmission — and directly motivated the drug maraviroc (a CCR5 antagonist) and the "Berlin patient" and "London patient" stem-cell transplant cures using CCR5-Δ32/Δ32 donor marrow.
Proof of the latent reservoir (Chun, Finzi, Siliciano labs, 1995–1997). Even in patients whose plasma viral load was suppressed to undetectable levels by combination antiretroviral therapy, three independent groups (Tae-Wook Chun and Anthony Fauci at NIH; Diana Finzi and Robert Siliciano at Johns Hopkins) isolated resting CD4⁺ memory T cells, activated them ex vivo with mitogens, and recovered replication-competent virus by viral outgrowth assay — culturing patient T cells with donor CD4⁺ target cells and measuring p24 antigen production. This proved that fully infectious provirus persists in a stable, resting reservoir despite years of therapy, with an estimated half-life of the latent reservoir of roughly 44 months — implying (at that decay rate) over 60 years to spontaneous clearance, explaining why treatment interruption reliably causes viral rebound within weeks and why HIV cure remains an active research problem rather than a routine outcome.
Quantifying bystander pyroptosis (Doitsh, Galloway, Greene et al., 2010, 2014). Using human lymphoid aggregate cultures (tonsil explants), the Greene lab showed that only a small minority of CD4⁺ T cells die by classical apoptosis from productive infection; the great majority die by caspase-1-dependent pyroptosis triggered by abortive infection attempts, and that pharmacologically blocking caspase-1 rescued CD4⁺ T cells from death in these cultures without blocking viral replication itself — direct causal evidence separating the mechanism of cell death from the mechanism of viral replication, and explaining the disproportionate scale of CD4⁺ collapse relative to the fraction of cells ever fully infected.
Worked examples
Example 1 — Interpreting a coreceptor tropism assay in a treatment decision. A patient beginning antiretroviral therapy is being evaluated for maraviroc (a CCR5 antagonist) eligibility. A genotypic tropism test sequences the env V3 loop from plasma virus and predicts receptor usage from sequence features (charge at V3 positions 11/25, per the "11/25 rule" and related algorithms). Result: 92% of sequenced clones are predicted R5-tropic, 8% X4-tropic. Reasoning: Maraviroc blocks only CCR5-dependent entry. If even a minor X4 or dual-tropic subpopulation exists below the assay's reliable detection threshold (~5–10% of the quasispecies, given assay sensitivity limits), that subpopulation can expand under CCR5-antagonist selective pressure, since it does not depend on CCR5 at all. Standard clinical practice therefore requires a tropism result of "R5-only" with acceptable assay sensitivity before prescribing maraviroc; a mixed/dual-tropic call (as here, at 8% X4) is generally treated as a contraindication, because the minority X4 population will simply replicate unopposed and cause therapy failure. This illustrates a core evolutionary point: selection acts on standing genetic diversity generated by error-prone reverse transcription, not on some idealized single "the virus."
Example 2 — Estimating reservoir decay and time to eradication. A patient has been on fully suppressive antiretroviral therapy for 3 years, with plasma viral load undetectable throughout. Using the viral outgrowth assay, the latent reservoir in resting CD4⁺ memory T cells is measured at time zero (start of suppression) at roughly 1 infectious unit per million (IUPM) resting CD4⁺ cells, and the published reservoir half-life is ~44 months. Question: assuming simple exponential decay, what fraction of the initial reservoir remains after 3 years (36 months), and how long would eradication take? Calculation: Remaining fraction = (1/2)^(t / t½) = (1/2)^(36/44) = (0.5)^0.818 ≈ 0.567 So about 57% of the original reservoir persists after 3 years — barely half-cleared. To reach, say, a 99.9% reduction (still not true zero, since latent cells are discrete units and stochastic extinction matters near very low numbers): 0.001 = (0.5)^(t/44) → t = 44 × log(0.001)/log(0.5) ≈ 44 × 9.97 ≈ 438 months ≈ 36.5 years. This calculation — close to estimates originally reported by Siliciano and colleagues — is the quantitative basis for the statement that lifelong antiretroviral therapy, not spontaneous decay, is required to control HIV, and why "cure" research focuses on actively purging or permanently silencing the reservoir rather than waiting it out.
Common misconceptions & traps
| Misconception | Why it's wrong |
|---|---|
| "HIV directly kills every CD4⁺ T cell it infects, and that alone explains AIDS." | Most CD4⁺ T-cell death occurs in bystander cells that were never productively infected, via pyroptosis triggered by abortive reverse transcription intermediates (Doitsh et al.). Direct cytopathic killing of productively infected cells is a minority contributor. |
| "Undetectable viral load means the virus is gone." | Undetectable plasma RNA (below ~20–50 copies/mL) reflects assay sensitivity, not absence of virus. The latent reservoir in resting memory CD4⁺ T cells persists, invisible to both drugs and immune surveillance, and rebounds within weeks if therapy stops. |
| "CD4 alone is the receptor for HIV." | CD4 binding is necessary but not sufficient; a coreceptor (CCR5 or CXCR4) must also be engaged before gp41-mediated fusion proceeds. Mouse CD4⁺ cells remain resistant because murine CCR5/CXCR4 do not support fusion efficiently. |
| "Antiretroviral therapy stops HIV replication and reverses latency." | ART blocks new rounds of infection (entry, RT, integrase, protease steps) but has no effect on already-integrated, transcriptionally silent provirus — latency is a state ART cannot address by mechanism. |
| "CCR5-Δ32 homozygotes are immune to all HIV." | They strongly resist R5-tropic strains (the majority of transmitted viruses) but remain susceptible to X4-tropic or dual-tropic strains that use CXCR4 instead. |
The scientist behind it
Origins · 1 minFrançoise Barré-Sinoussi and how this was discovered
Barré-Sinoussi trained as a virologist under Luc Montagnier at the Institut Pasteur, working initially on retroviruses in animal models. In 1983, presented with a lymph node biopsy from a patient with unexplained lymphadenopathy — an early, atypical AIDS presentation — she detected reverse transcriptase activity in cultured lymphocyte supernatant within days, a chemical signature that only a retrovirus could produce. Rather than assuming the agent was a known human retrovirus (HTLV, then recently discovered and associated with leukemia, not immune collapse), she and Montagnier pursued electron microscopy and immunological cross-reactivity studies that revealed a genuinely novel retrovirus, distinct from HTLV, budding from infected lymphocytes with the morphology characteristic of lentiviruses. Her insistence on rigorously distinguishing this virus from HTLV — against considerable early scientific and institutional pressure — was vindicated as the isolate (LAV) was confirmed worldwide as the cause of AIDS. She continued decades of work on mechanisms of viral control in rare "elite controller" patients who suppress HIV without treatment, informing later vaccine and cure research.
Where this matters today
Antiretroviral drug design exploits every mechanistic step described above: entry inhibitors (maraviroc, a CCR5 antagonist; enfuvirtide, a gp41 fusion inhibitor), nucleoside/non-nucleoside reverse transcriptase inhibitors, integrase strand-transfer inhibitors (dolutegravir, bictegravir — now first-line therapy), and protease inhibitors that block Gag/Gag-Pol maturation. Modern combination regimens, by hitting multiple independent steps simultaneously, suppress viral load to undetectable levels and make transmission risk negligible (U=U), transforming HIV/AIDS from a near-certain death sentence into a manageable chronic condition for patients with medication access.
Pre-exposure prophylaxis (PrEP) uses reverse transcriptase inhibitors (tenofovir/emtricitabine, or long-acting injectable cabotegravir, an integrase inhibitor) prophylactically in HIV-negative individuals at risk, blocking establishment of infection at the earliest replication steps before a reservoir can form.
Cure research directly targets the latency mechanism described above. "Shock and kill" strategies use latency-reversing agents (histone deacetylase inhibitors, PKC agonists) to force transcriptional reactivation of silent provirus, exposing infected cells to immune clearance or viral cytopathic effect while ART blocks new spread. "Block and lock" strategies pursue the opposite goal — permanently deepening proviral silencing. Gene-editing approaches (CRISPR-based excision of integrated provirus, or CCR5 gene editing to mimic the natural Δ32 resistance allele) are in active preclinical and early clinical development, directly inspired by the CCR5-Δ32 natural experiment and by the handful of documented cures achieved through allogeneic CCR5-Δ32/Δ32 stem-cell transplantation (the Berlin, London, and subsequent patients).
Vaccine design confronts the reverse-transcription error rate and resulting antigenic diversity described in the mechanism section: because RT lacks proofreading, HIV's envelope glycoprotein diversifies faster than most immune responses can track, which is why decades of vaccine trials targeting single strain-specific epitopes have largely failed, and current efforts focus on eliciting broadly neutralizing antibodies against conserved gp120/gp41 structural elements. This mechanistic and evidentiary foundation feeds directly into understanding Viral Pathogenesis and Host Damage more broadly — how persistent immune activation, not just direct cytolysis, drives disease across many chronic viral infections — and into the rational logic of Antiviral Strategies and Drug Targets, where each step of the replication cycle mapped here becomes a distinct pharmacological target.
Ask the tutor: How exactly does the Tat–TAR–P-TEFb feedback loop turn a "leaky" latent provirus into a full productive infection once a resting T cell is reactivated?
Why does HIV need two receptors instead of one, like most viruses?
Sequential CD4-then-coreceptor engagement adds a layer of conformational proofreading: CD4 binding alone triggers gp120 to expose a coreceptor-binding surface that is otherwise hidden, protecting this vulnerable epitope from neutralizing antibodies until the last possible moment before fusion. This two-step mechanism also allows HIV to exploit tissue-specific tropism — CCR5 on macrophages and mucosal CD4⁺ T cells for transmission and early infection, CXCR4 on more differentiated T cells for late-stage disseminated disease — effectively using coreceptor choice as a biological switch between transmission-optimized and pathogenesis-optimized viral behavior across disease stages.
Is HIV latency the same thing as viral dormancy in herpesviruses?
Both involve transcriptionally silent, genome-persisting infection, but the mechanisms differ substantially. Herpesviruses maintain latency as extrachromosomal episomes with dedicated latency-associated transcripts and can reactivate through well-characterized viral switches. HIV latency instead depends on chromosomal integration into host DNA at essentially random (though transcriptionally-biased) sites, with silencing driven almost entirely by the host cell's own resting-state chromatin environment rather than a dedicated viral latency program. This is why HIV latency is often described as accidental — a byproduct of infecting cells that happen to be resting — rather than an evolved viral strategy in the same sense as herpesvirus latency.
What does "undetectable = untransmittable" (U=U) actually mean mechanistically?
Suppressive antiretroviral therapy reduces plasma HIV RNA below the detection threshold of standard assays (typically <20–50 copies/mL) by blocking essentially all new infection cycles — entry, reverse transcription, integration, or maturation, depending on the drug class. With replication halted, free infectious virus in blood and genital secretions falls to levels below what multiple large clinical studies (PARTNER, PARTNER2, HPTN 052) found sufficient to transmit infection through sex, even across thousands of condomless sexual acts in serodifferent couples. Importantly, this does not mean the latent reservoir is gone — it means active virion production, the only source of new transmission, has been effectively shut down.
Why is CXCR4-tropic HIV associated with more advanced, aggressive disease?
Epidemiologically, R5-tropic strains dominate transmission and early infection, while X4-tropic (or dual-tropic) variants emerge later in a substantial fraction of patients as the virus diversifies under selective pressure. X4 strains can infect a broader range of CD4⁺ T-cell subsets, including naive T cells, and their emergence correlates with accelerated CD4⁺ decline and faster progression to AIDS — though whether the coreceptor switch is a cause or simply a marker of advancing immune deterioration remains an active area of investigation, and the correlation, while robust, is not fully mechanistically resolved.
How was it proven that CD4 alone is insufficient for HIV entry, motivating the search for a coreceptor?
Researchers transfected the human CD4 gene into non-human cell lines (including mouse cells) and observed that these cells could bind HIV gp120 but remained resistant to productive infection and syncytium formation — a direct experimental dissociation of binding from fusion. This gain-of-function-but-incomplete result told researchers a second, human-specific factor absent from mouse cells was required, motivating the expression-cloning strategy that Edward Berger's lab used in 1996 to fish out CXCR4 as the missing coreceptor, rapidly followed by identification of CCR5 for macrophage-tropic strains.
Can the latent reservoir ever be measured directly, and how large is it?
Yes, primarily via the quantitative viral outgrowth assay, which activates patient resting CD4⁺ T cells ex vivo and measures replication-competent virus recovered per million cells (infectious units per million, IUPM). Typical values in ART-suppressed patients are roughly 0.1–10 IUPM, translating to an estimated total body reservoir on the order of 10⁵–10⁷ latently infected cells — small compared to total CD4⁺ T-cell numbers (roughly 10¹¹ total), but sufficient, given the reservoir's estimated ~44-month half-life, to guarantee viral rebound within weeks of any treatment interruption for the foreseeable future without a dedicated cure intervention.
What happens to CD4⁺ T cells in the gut early in infection, and why does it matter?
Gut-associated lymphoid tissue (GALT) contains a very high density of activated, CCR5-expressing memory CD4⁺ T cells — an ideal target population — and studies of acutely infected patients and SIV-infected macaques show that a large fraction of GALT CD4⁺ T cells are destroyed within the first weeks of infection, well before peripheral blood CD4⁺ counts show much change. This early mucosal destruction compromises gut epithelial barrier integrity, allowing microbial products to translocate into circulation and drive the chronic systemic immune activation that itself accelerates disease progression — linking the entry/replication mechanism directly to the chronic inflammatory pathology of AIDS.